Computational Challenges in Cancer Therapeutics

Friday, May 1, 2009 - 1:25pm - 2:25pm
Vincent 570
Paul Rejto (Pfizer Global R&D)
Recent advances have dramatically advanced our understanding of cancer
at the molecular level. In turn, new therapeutic agents that target
specific molecular defects in cancer have been developed, though cancer
remains a significant health threat. Following an introduction to the
molecular biology of cancer, a statistical approach to distinguish
driver mutations from passengers based on non-random clustering will be
discussed. Next, approaches to pharmaceutical intervention will be
reviewed and an integrated approach to link targeted therapeutics with
specific patient populations will be shown. Throughout, open questions
will be presented with a focus on problems of potential mathematical

MSC Code: